What The Study Did: This randomized clinical trial compared the outcomes of heart attack, stroke or death from cardiovascular causes among 6,000 patients with type 2 diabetes who were treated with the glucose-lowering medications linagliptin or glimepiride.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Authors: Nikolaus Marx, M.D., of Aachen University in Aachen, Germany, is the corresponding author.
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.